Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

  • Discontinued
  • GID-TA10234
The company (Bristol-Myers Squibb) requested that NICE suspend this appraisal because of a change to its regulatory timelines for this indication. Therefore, the discussion of this topic at the appraisal committee meeting (previously scheduled for 8 November 2018) will be rescheduled. We will provide a further update and rescheduled timelines in due course.